These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 26118499)

  • 21. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
    Gooding S; Edwards CM
    Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel targeted agents in the treatment of multiple myeloma.
    Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights into therapeutic targets in myeloma.
    Anderson KC
    Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.
    Heider M; Nickel K; Högner M; Bassermann F
    Oncol Res Treat; 2021; 44(12):672-681. PubMed ID: 34749378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
    Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
    Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panobinostat: a review of trial results and future prospects in multiple myeloma.
    Libby EN; Becker PS; Burwick N; Green DJ; Holmberg L; Bensinger WI
    Expert Rev Hematol; 2015 Feb; 8(1):9-18. PubMed ID: 25410127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Bone Marrow Microenvironment.
    Moschetta M; Kawano Y; Podar K
    Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the treatment of Multiple Myeloma.
    Yasui H; Hideshima T; Richardson PG; Anderson KC
    Curr Pharm Biotechnol; 2006 Oct; 7(5):381-93. PubMed ID: 17076653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
    Von Suskil M; Sultana KN; Elbezanti WO; Al-Odat OS; Chitren R; Tiwari AK; Challagundla KB; Srivastava SK; Jonnalagadda SC; Budak-Alpdogan T; Pandey MK
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
    Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
    Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
    Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
    Tang W; Xu J; Xu C
    Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.